Drug Monograph
Fluphenazine
Prolixin (oral/IM HCl) · Prolixin Decanoate (long-acting IM/SC depot)
Pharmacokinetic Profile
Half-Life
14–16 h (oral); 6.8–9.6 days (decanoate)
Metabolism
CYP2D6 (primary substrate); metabolised to fluphenazine sulfoxide
Protein Binding
>90%
Bioavailability
~2.7% (oral; extensive first-pass)
Volume of Distribution
~298 L
Clinical Information
Drug Class
High-potency first-generation (typical) antipsychotic
Available Doses
Tabs: 1, 2.5, 5, 10 mg; Elixir: 2.5 mg/5 mL; Concentrate: 5 mg/mL; IM HCl: 2.5 mg/mL; Decanoate: 25 mg/mL
Route
Oral; IM (HCl and decanoate); SC (decanoate only)
Renal Adjustment
Use with caution
Hepatic Adjustment
Contraindicated in liver damage; use with caution in hepatic impairment
Pregnancy
Risk of neonatal EPS/withdrawal with 3rd-trimester use
Lactation
Not recommended; excreted in breast milk
Schedule
Not a controlled substance
Generic Available
Yes (Prolixin brand discontinued in US)
Black Box Warning
Yes — Elderly dementia mortality
CPZ Equivalence
2 mg fluphenazine PO ≈ 100 mg chlorpromazine
Indications for Fluphenazine
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Schizophrenia (oral and IM HCl) | Adults | Monotherapy | FDA Approved |
| Chronic schizophrenia requiring prolonged parenteral therapy (decanoate depot) | Adults stabilised on oral fluphenazine | Maintenance monotherapy | FDA Approved |
Fluphenazine is a high-potency piperazine phenothiazine antipsychotic that was the first FDA-approved injectable long-acting antipsychotic (1968). Its decanoate depot formulation remains on the WHO List of Essential Medicines and provides a cost-effective option for maintenance treatment of schizophrenia in patients with adherence challenges. While its use has declined substantially in developed countries following the introduction of second-generation long-acting injectables, fluphenazine decanoate remains widely used globally because of its low cost, established track record, and predictable pharmacokinetics.
Off-Label Uses
Psychotic symptoms in neurocognitive disorders (evidence quality: low): Frequently prescribed off-label but not FDA-approved for dementia-related psychosis. Carries boxed warning for increased mortality in elderly patients with dementia-related psychosis.
Dosing for Fluphenazine
Oral Dosing — Adults
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Schizophrenia — initial treatment | 2.5–10 mg/day PO in 2–3 divided doses (q6–8h) | 1–5 mg/day (often as single daily dose) | 20 mg/day (usual); up to 40 mg/day (acute, short-term) | Most patients achieve therapeutic effect at <20 mg/day; chronic use >40 mg/day not established Reduce to lowest effective maintenance dose once response achieved |
| Elderly patients | 1–2.5 mg/day PO | Adjust per response | Individualise cautiously | Increased sensitivity to EPS, orthostatic hypotension, and anticholinergic effects |
IM HCl (Short-Acting) — Adults
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Acute psychosis — unable to take oral | 2.5–10 mg/day IM in divided doses q6–8h | Switch to oral ASAP | 10 mg/day IM | IM only (not IV or SC for HCl salt); keep patient supine ≥30 min post-injection Oral dose = 2–3× IM HCl dose |
Decanoate Depot (Long-Acting Injectable) — Adults
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Schizophrenia maintenance — transition from oral | 12.5–25 mg IM or SC | 12.5–100 mg q2–4 wk (individualise) | 100 mg per injection | Onset 24–72 h; significant effect within 48–96 h; effect lasts 2–6 wk (avg 3–4 wk) If >50 mg needed, increase cautiously by 12.5 mg increments |
| PORT guideline maintenance range | 6.25–25 mg IM q2 wk | 100 mg per injection | Evidence-based maintenance range from Schizophrenia PORT recommendations | |
| “Poor risk” patients (phenothiazine-sensitive) | Start with oral/IM HCl to establish tolerance | Convert to equivalent decanoate dose once stable | 100 mg per injection | Determine response and appropriate dosage with shorter-acting formulation first |
Clinical Pearl: Oral-to-Depot Conversion
The Schooler (1976) multicentre study established the standard conversion: 20 mg oral fluphenazine HCl daily is approximately equivalent to 25 mg (1 mL) fluphenazine decanoate every 3 weeks. This yields a working ratio of 12.5 mg decanoate every 3 weeks for every 10 mg oral daily. However, there is substantial interindividual variation, and clinical monitoring at each injection is essential to find the optimal dose and interval for each patient.
Pharmacology of Fluphenazine
Mechanism of Action
Fluphenazine is a high-potency piperazine phenothiazine that exerts its antipsychotic effect primarily through potent antagonism of postsynaptic dopamine D2 receptors in the mesolimbic and mesocortical pathways. It also blocks D1 receptors, alpha-1 adrenergic receptors, muscarinic M1 receptors, and histamine H1 receptors, though with considerably less affinity at H1 and muscarinic sites compared to low-potency phenothiazines such as chlorpromazine. This pharmacological profile gives fluphenazine a clinical character more similar to haloperidol than to chlorpromazine: less sedation, less orthostatic hypotension, and less anticholinergic burden, but significantly more extrapyramidal symptoms at therapeutic doses. The decanoate ester is a prodrug that is hydrolysed by tissue esterases to release active fluphenazine from the sesame oil depot.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Oral: rapid absorption; Tmax ~2 h; bioavailability only ~2.7% due to extensive first-pass metabolism. Decanoate IM/SC: onset of clinical effect 24–72 h; initial early plasma spike within first day (1–8 h post-injection) followed by stable sustained release; flip-flop kinetics (absorption rate-limited elimination) | Extremely low oral bioavailability means the depot route provides far more predictable drug exposure; explains why depot is preferred for adherence-critical situations |
| Distribution | Vd ~298 L; protein binding >90%; highly lipophilic; crosses blood-brain barrier; tissue uptake extensive | Large volume of distribution contributes to prolonged tissue retention; decanoate dissolves in sesame oil creating a localised depot from which drug slowly diffuses |
| Metabolism | Hepatic via CYP2D6 (primary); metabolised to fluphenazine sulfoxide (major metabolite); weak inhibitor of CYP2C9 and CYP2E1; decanoate is a prodrug hydrolysed by esterases | CYP2D6 poor metabolisers may have elevated levels and increased EPS risk; monitor for drug interactions with CYP2D6 inhibitors (fluoxetine, paroxetine, quinidine) |
| Elimination | t½ 14–16 h (oral); 6.8–9.6 days (decanoate); excreted in urine and faeces; therapeutic window 0.2–2.8 ng/mL | Decanoate half-life supports q2–4 week dosing intervals; wide interindividual variability requires clinical monitoring over plasma level monitoring |
Side Effects of Fluphenazine
≥10%Very Common
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Extrapyramidal symptoms (composite) | 20–40% | Comparable to haloperidol; includes parkinsonism, dystonia, akathisia; dose-related; highest of phenothiazine subclass |
| Akathisia | 15–30% | Can be extremely distressing; propranolol or benzodiazepines may help; dose reduction often necessary |
| Hyperprolactinaemia | >50% (biochemical) | Potent D2 blockade consistently raises prolactin; may cause amenorrhoea, galactorrhoea, sexual dysfunction |
1–10%Common
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Sedation / Drowsiness | 5–15% | Less sedating than chlorpromazine; more common during dose titration |
| Orthostatic hypotension | 5–10% | Less pronounced than low-potency FGAs but clinically relevant, especially after IM injection |
| Dry mouth / Constipation | 5–10% | Moderate anticholinergic burden; less than chlorpromazine |
| Blurred vision | 3–8% | Anticholinergic mydriasis; use with caution in narrow-angle glaucoma |
| Weight gain | 3–8% | Less than chlorpromazine or SGAs; minimal metabolic burden compared to olanzapine or clozapine |
| Injection-site reactions (decanoate) | 2–5% | Nodule formation, pain, erythema at injection site; rotate sites; use 21-gauge needle with dry syringe |
SeriousSerious (Regardless of Frequency)
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Tardive dyskinesia | ~5% per year (FGA class rate) | Months to years; cumulative risk; higher in elderly women | Consider discontinuation or switch to SGA; VMAT2 inhibitors for established TD |
| Neuroleptic malignant syndrome | Rare (~0.01–0.02%) | Days to weeks after initiation or dose increase | Immediate discontinuation; ICU supportive care; dantrolene or bromocriptine may be considered; particular caution with depot because drug cannot be withdrawn once injected |
| QTc prolongation | Uncommon (dose-related) | Any time | Baseline ECG; avoid concurrent QT-prolonging drugs; correct electrolytes |
| Hepatic abnormalities | Up to 40% mild LFT elevation with chronic phenothiazine use | Weeks to months | Monitor LFTs; discontinue if clinically significant hepatotoxicity develops |
| Agranulocytosis / Blood dyscrasias | Rare | Weeks to months | CBC monitoring; warn patient to report sore throat, fever; discontinue if confirmed |
DiscontinuationDiscontinuation Considerations
Depot Washout
Weeks to months
The decanoate formulation cannot be “withdrawn” once injected. If serious adverse effects occur, their management must account for continued drug release from the depot site for several weeks.
Oral Withdrawal
Taper gradually
Abrupt cessation may cause nausea, vomiting, restlessness, sweating, and insomnia. Withdrawal dyskinesia can emerge. Gradual dose reduction recommended.
Depot Formulation and NMS Risk
If NMS or another serious adverse reaction occurs in a patient receiving fluphenazine decanoate, the treating team must recognise that the drug will continue to be released from the depot site for weeks. This means supportive care and monitoring must extend well beyond the acute episode. For this reason, the Prolixin PI recommends that patients without prior phenothiazine exposure be started on a shorter-acting oral or IM HCl formulation first to establish tolerance and appropriate dosing before transitioning to the depot.
Drug Interactions with Fluphenazine
Fluphenazine is a major substrate of CYP2D6 and a weak inhibitor of CYP2C9 and CYP2E1. Like other phenothiazines, it can potentiate CNS depressants and produce alpha-adrenergic blockade. The long-acting depot formulation makes interaction management particularly important, since dose adjustments take weeks to take effect.
MajorCNS Depressants / Opioids / Alcohol
MechanismAdditive CNS and respiratory depression
EffectExcessive sedation, respiratory depression, hypotension; however, fluphenazine has less potentiating effect on CNS depressants than low-potency phenothiazines
ManagementUse lowest effective doses; monitor closely; avoid alcohol
FDA PIMajorCYP2D6 Inhibitors (fluoxetine, paroxetine, quinidine, bupropion)
MechanismInhibition of primary metabolic pathway; increased fluphenazine plasma levels
EffectElevated EPS risk, excessive sedation, QTc prolongation
ManagementConsider dose reduction of fluphenazine; monitor for adverse effects; extra caution with depot formulation since dose cannot be quickly reduced
StatPearlsMajorQTc-Prolonging Agents
MechanismAdditive QTc prolongation
EffectIncreased risk of torsades de pointes
ManagementAvoid co-prescription when possible; baseline ECG; correct electrolytes
FDA PIModerateLevodopa / Dopamine Agonists
MechanismPharmacological antagonism at D2 receptors
EffectMutual attenuation of therapeutic effects
ManagementAvoid concurrent use; use quetiapine, clozapine, or pimavanserin for psychosis in Parkinson’s
FDA PIModerateLithium
MechanismUnknown; rare encephalopathic syndrome reported with phenothiazine-lithium combination
EffectWeakness, lethargy, fever, confusion, EPS; may be irreversible in rare cases
ManagementMonitor closely for early neurological signs; discontinue promptly if encephalopathic signs appear
FDA PIModerateAnticholinergic Agents
MechanismAdditive anticholinergic effects
EffectIncreased constipation, urinary retention, delirium risk, heat intolerance
ManagementMonitor anticholinergic burden; benztropine co-prescription for EPS should use lowest effective dose
FDA PIMonitoring for Fluphenazine
- EPS AssessmentEach visit / each depot injection
RoutineHigh-potency agent with substantial EPS risk. Assess for akathisia, parkinsonism, dystonia at every injection visit. AIMS assessment at least every 6 months; every 3 months in elderly. - ECGBaseline; as clinically indicated
RoutineBaseline ECG recommended in patients with cardiac conduction abnormalities. Monitor for QTc changes, especially with concurrent QT-prolonging medications. - CBCBaseline; periodically
RoutineMonitor for leukopenia, neutropenia; warn patients to report sore throat, fever, or signs of infection. - LFTsBaseline; periodically
RoutineUp to 40% of patients on chronic phenothiazines develop mild LFT abnormalities. Clinically significant hepatotoxicity is uncommon but requires discontinuation. - Metabolic PanelBaseline, 12 wk, then annually
RoutineFasting glucose, HbA1c, lipids, weight. Lower metabolic risk than SGAs but monitoring remains standard per APA guidelines. - Renal FunctionBaseline; periodically
RoutineBUN and creatinine monitoring, particularly in patients with pre-existing renal disease or concurrent nephrotoxic drugs. - Prolactin LevelIf symptomatic
Trigger-basedCheck if amenorrhoea, galactorrhoea, sexual dysfunction, or gynaecomastia develop. Consider switching to prolactin-sparing agent if symptomatic.
Contraindications & Cautions for Fluphenazine
Absolute Contraindications
- Known hypersensitivity to fluphenazine or other phenothiazines (cross-sensitivity may occur).
- Suspected or established subcortical brain damage.
- Comatose or severely depressed states.
- Blood dyscrasias or existing bone marrow depression.
- Liver damage or active hepatic disease.
- Concomitant use of large doses of hypnotics.
Relative Contraindications (Specialist Input Recommended)
- Severe depression — fluphenazine decanoate specifically should not be used in patients with severe depression (risk of worsening).
- Patients phenothiazine-naive — establish tolerance with oral/IM HCl before depot.
Use with Caution
- Cardiovascular disease (risk of hypotension, QTc effects)
- Seizure history (lowers seizure threshold)
- Elderly patients (increased EPS, TD, and falls risk)
- Renal impairment
- Patients exposed to extreme heat or organophosphorus insecticides
- Patients on multiple CYP2D6-metabolised drugs
FDA Boxed Warning
Increased Mortality in Elderly Patients with Dementia-Related Psychosis
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death (1.6–1.7× versus placebo). Deaths were primarily cardiovascular or infectious. Fluphenazine is not approved for dementia-related psychosis.
Patient Counselling for Fluphenazine
Purpose of Therapy
Fluphenazine helps control symptoms of schizophrenia by adjusting the balance of dopamine, a natural chemical in the brain. It is available as tablets or as a long-acting injection given every 2 to 4 weeks. The injection ensures a steady level of medication in your body, which can help prevent symptom relapses.
How to Take
If taking tablets, take them at the same times each day in divided doses (usually 2–3 times daily). If receiving the long-acting injection, attend all scheduled clinic appointments. Do not stop your medication abruptly without consulting your prescriber, as withdrawal symptoms may occur. Store tablets at room temperature protected from light.
Movement Problems (EPS)
Tell patientMuscle stiffness, tremor, restlessness, or unusual movements are the most common side effects of fluphenazine. Tell your prescriber immediately about any new movement symptoms — most can be managed with dose adjustment or additional medication.
Call prescriberUrgently if you develop a stiff neck, difficulty swallowing, eyes rolling upward, high fever with severe rigidity, or uncontrollable movements of the face or tongue.
Depot Injection Schedule
Tell patientKeeping to your injection schedule is very important. The injection provides medication for 2–4 weeks. If you miss an appointment, contact your clinic as soon as possible to reschedule.
Call prescriberIf you miss your injection by more than a few days or if symptoms begin to return before your next scheduled injection.
Drowsiness & Dizziness
Tell patientYou may experience some drowsiness or dizziness, particularly early in treatment or after dose increases. Avoid driving or operating machinery until you know how this medication affects you. Rise slowly from sitting or lying positions.
Call prescriberIf drowsiness is severe or if you faint or fall.
Hormonal Effects
Tell patientThis medication may raise a hormone called prolactin, which can cause missed periods, breast discharge, or sexual difficulties in both men and women. These effects are usually reversible.
Call prescriberIf you develop persistent menstrual changes, breast discharge, or troubling sexual side effects.
Sources
Regulatory (PI / SmPC)
- Prolixin Decanoate (fluphenazine decanoate injection). Full Prescribing Information. Drugs.com PIPrimary source for decanoate depot dosing, oral-to-depot conversion ratio, onset/duration of action, contraindications, and adverse reactions.
- Prolixin (fluphenazine hydrochloride) Tablets/Elixir/Injection. Full Prescribing Information. Drugs.com PISource for oral and IM HCl dosing, geriatric dosing, contraindications (subcortical brain damage, blood dyscrasias, liver damage), and precautions.
- Fluphenazine Decanoate Injection, USP. FDA Label. FDA LabelFDA-approved label with maximum 100 mg dose limit and dosing guidance for resistant patients.
Key Clinical Trials
- Schooler NR. The initiation of long-term pharmacotherapy in schizophrenia: dosage and side effect comparisons between oral and depot fluphenazine. Pharmakopsych. 1976;9:159-169.Landmark multicentre study establishing the oral-to-depot fluphenazine conversion ratio (20 mg oral daily ≈ 25 mg decanoate q3wk).
- Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951-962. DOINetwork meta-analysis including fluphenazine among 15 antipsychotics; helps contextualise efficacy and tolerability relative to other agents.
- Maayan N, Quraishi SN, David A, et al. Fluphenazine decanoate (depot) and enanthate for schizophrenia. Cochrane Database Syst Rev. 2015;(2):CD000307. DOICochrane systematic review of fluphenazine depot efficacy and tolerability; confirms clinical utility but notes high EPS rates.
- Sampford JR, Sampson S, Li BG, et al. Fluphenazine (oral) versus atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2016;7(7):CD010832. DOICochrane review comparing oral fluphenazine to SGAs; limited evidence that SGAs were more tolerable.
Guidelines
- Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia. Am J Psychiatry. 2020;177(9):868-872. DOIAPA guideline recommending LAI antipsychotics for patients with adherence challenges; fluphenazine decanoate is a cost-effective FGA option.
- Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 Schizophrenia PORT psychopharmacological treatment recommendations. Schizophr Bull. 2010;36(1):71-93. DOIPORT guidelines recommending fluphenazine decanoate 6.25–25 mg q2wk as an evidence-based maintenance dose range.
Pharmacokinetics / Special Populations
- Koytchev R, Alken RG, McKay G, Katzarov T. Absolute bioavailability of oral immediate and slow release fluphenazine in healthy volunteers. Eur J Clin Pharmacol. 1996;51(2):183-187. DOIPK study in healthy volunteers establishing oral bioavailability at 2.7% for immediate release and 3.4% for slow release formulations.
- Correll CU, Kim E, Sliwa JK, et al. Pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: an overview. CNS Drugs. 2021;35(1):39-59. DOIComprehensive PK review of all LAI antipsychotics including fluphenazine decanoate; covers half-life, flip-flop kinetics, and depot characteristics.
- Fluphenazine. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. NCBIClinical review covering mechanism, dosing, CYP2D6 metabolism, monitoring, and adverse effects of fluphenazine.